MedTrace Logo

Effects of High Intensity Interval Training and Combined Training in Type 2 Diabetic (T2D) Patients

NCT03593746 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-05-17

No results posted yet for this study

Summary

Diabetes has become a widespread epidemic, primarily because of the increasing prevalence and incidence of type 2 diabetes (T2D). T2D is a significant cause of premature mortality and morbidity related to cardiovascular disease, blindness, kidney and nerve disease, and amputation.

Physical activity improves blood glucose control and can prevent or delay T2D, along with positively affecting lipids, blood pressure, cardiovascular events, mortality, and quality of life. At present, although physical activity is a key element in the prevention and management of T2D, the most effective exercise strategy (intensity, duration, and type of exercise) for improving glucose control and reducing cardiometabolic risk in type 2 diabetes has not been defined.

Studies with Light-Emitting Diode (LED) therapy have demonstrated its ability to promote pain relief, improve muscle and cardiopulmonary performance, minimize muscle fatigue, and stimulate wound healing. In relation to patients with T2D, who have prolonged conditions of hyperglycemia, studies to investigate the impact of photobiomodulation associated with physical training have not been found so far.

The objective of this study is to investigate the effects of different types of physical training associated with Light-Emitting Diode (LED) therapy on cardiometabolic status and quality of life in patients with T2D.

Conditions

  • Diabetes Mellitus, Type 2
  • High-Intensity Interval Training
  • Exercise Training
  • Hyperglycaemia Due to Type 2 Diabetes Mellitus

Interventions

OTHER

Physical training

Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).

OTHER

Light-Emitting Diode (LED) therapy

Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).

Sponsors & Collaborators

  • University of Nove de Julho

    lead OTHER

Principal Investigators

  • Luciana MM Sampaio, Professor · Nove de Julho University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-10-01
Completion
2022-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593746 on ClinicalTrials.gov